Program
Liraglutide
Also written as “liraglutide”, “insulin degludec/liraglutide” and “Insulin degludec/liraglutide”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Diabetes Mellitus, Type 1 · Osteoarthritis, Knee, led by 10 companies.
Drug pageLiraglutide: every studyMany companies study it; this page follows only the 109 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 972 open or running | phase 4since Jul 22, 2013 | Sep 8, 2005 | Dec 13, 2026phase 1 · NCT07225816 |
| 4Moving Biotechits history only | 20 open or running | phase 2since Sep 24, 2025 | Jun 7, 2022 | none ahead |
| Eli Lillyits history only | 20 open or running | phase 4since Feb 24, 2014 | May 31, 2013 | none ahead |
| Tonghua Dongbao Pharmaceuticalits history only | 22 open or running | phase 3since Aug 14, 2024 | Jun 2, 2024 | none ahead |
| Biolingusits history only | 11 open or running | phase 2since Feb 16, 2022 | Feb 16, 2022 | none ahead |
| Cinnagen | 10 open or running | phase 3since Jan 29, 2018 | Jan 29, 2018 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Sep 17, 2010 | Sep 17, 2010 | none ahead |
| Merckits history only | 10 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Feb 1, 2017 | Feb 1, 2017 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Aug 24, 2021 | Aug 24, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Cinnagen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2018First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT03421119 · 300 enrolled
TargetBeta
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
The one study Cinnagen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03421119Diabetes Mellitus, Type 2 | 3 | UNKNOWN | Dec 1, 2019 | 300 |
How it is read
Names in the registry
- “liraglutide”, 114 entries
- “insulin degludec/liraglutide”, 11 entries
- “Liraglutide”, 10 entries
- “Insulin degludec/liraglutide”, 3 entries
- “NN9924 (oral)”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 75 studies
- Obesity, 18 studies
- Diabetes Mellitus, 14 studies
- Diabetes Mellitus, Type 1, 5 studies
- Osteoarthritis, Knee, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.